Results 121 to 130 of about 14,756 (228)

Köbner Phenomenon in a Rituximab-Treated Pemphigus Patient: Beware Disease Activity

Dermatology Practical & Conceptual, 2019
Soheil Tavakolpour, Hamidreza Mahmoudi, Nika Kianfar, Shayan Dasdar, Maryam Daneshpazhooh   +4 more
doaj   +1 more source

Autoimmune bullous disease in skin of color: A case series. [PDF]

JAAD Case Rep, 2020
Tamazian S, Simpson CL.
europepmc   +1 more source

Autoimmune Bullous Diseases

TURKDERM, 2011
Lior Sagi, Sharon Baum, Nancy Agmon-Levin, Yaniv Sherer, Bat Sheva Porat Katz, Ori Barzilai, Maya Ram, Nicola Bizzaro, Marielle SanMarco, Henri Trau, Yehuda Shoenfeld   +10 more
openaire   +2 more sources

Scoring Criteria for Autoimmune Bullous Diseases: Utility, Merits, and Demerits

Indian Dermatology Online Journal
Background: Scoring systems play a crucial role in dermatology by providing objective measurements of disease severity, treatment efficacy, and outcome comparisons. In autoimmune blistering diseases (AIBDs), standardized scoring systems are essential for
Henry Tseng, Corey Stone, Dédée F. Murrell   +2 more
doaj   +1 more source

Redefining skin toxicity in the age of precision immunotherapy

Journal of the European Academy of Dermatology and Venereology, Volume 40, Issue 5, Page 716-717, May 2026.
Florentia Dimitriou, Christian Posch
wiley   +1 more source

Mast cell expression in pemphigus vulgaris and bullous pemphigoid: insights from cd117 immunohistochemistry and its relation to disease severity

Journal of the Egyptian Women’s Dermatologic Society
Background Pemphigus vulgaris (PV) and bullous pemphigoid (BP) are autoimmune bullous diseases which imply different pathogenic mechanisms. Mast cells (MCs) are resident immune cells that are involved in localized immune responses. Their incorporation in
Nagat S. Mohamed, Maram M. Allam, Asmaa H. Abd Ellatif, Eman M. Hassan   +3 more
doaj   +1 more source

Skin-Related Quality of Life During Autoimmune Bullous Disease Course.

JAMA Dermatol, 2023
Hopkins ZH, Jimenez A, Taliercio VL, Clarke JT, Hansen CB, Hull CM, Rhoads JLW, Zone JJ, Sahni VN, Kean J, Secrest AM.   +10 more
europepmc   +1 more source

Bullous dermatoses secondary to anti-PD-L1 agents: a case report and review of the literature [PDF]

, 2019
Immune checkpoint inhibitors are used to treat numerous malignancies but may be associated with severe adverse events. Bullous dermatoses, chiefly bullous pemphigoid (BP), are potentially progressive adverse events that cause blistering skin lesions and ...
Choi, Jennifer N, Kosche, Cory, Owen, Joshua L, Sadowsky, Lauren M   +3 more
core  

The Autoimmune Bullous Diseases

Journal of the Royal College of Physicians of London, 1997
S H, Wakelin, M M, Black
openaire   +2 more sources

Autoimmune bullous skin diseases.

Ensho, 1996
Interference with either keratinocyte-keratinocyte adhesion or epidermal basement membrane zone develops skin lesions in autoimmune bullous skin diseases by autoimmune mechanisms. The most important machinery for the cell-cell adhesion and dermo-epidermal adhesion is the desmosome and hemidesmosome, respectively.Recent studies using cDNAs for the ...
openaire   +2 more sources